Scl-70 antibodies

Anti-Scl-70 is the test to determine the quantity of IgG antibodies to Scl-70 (DNA topoisomerase I) in human serum.

These antibodies are a generally accepted and highly specific marker of progressive systemic scleroderma with about 100% specificity; autoantibodies to topoisomerase I are extremely rare in both healthy population and non-autoimmune population. In addition to systemic scleroderma serological diagnosis, the test is also useful for Raynaud's phenomenon differential diagnosis. Topoisomerase I autoantibodies are also prognostic marker of further systemic sclerosis development.

What is the study used for?

• autoimmune diseases diagnosis (systemic connective tissue diseases);

• differential diagnosis of some systemic autoimmune diseases of connective tissue;

• systemic scleroderma and CREST syndrome diagnosis.

When is the study scheduled?

• systemic scleroderma symptoms (specific damage of skin, blood vessels, joints and muscles, heart, lungs, gastrointestinal tract and kidneys due to generalized fibrosis in these organs) and CREST syndrome (calcification, Raynaud's phenomenon, esophageal motility disorders, sclerodactyly and telangiectasia);

• when detecting antinuclear factor and antinuclear antibodies in blood;

assess the systemic connective tissue diseases dynamics.